Astellas Pharma Inc. (ALPMF)
| Previous close | 0.00 |
| Open | 11.00 |
| Bid | 10.65 x 40000 |
| Ask | 12.75 x 40000 |
| Day's range | 11.00 - 11.10 |
| 52-week range | 9.13 - 13.54 |
| Volume | |
| Avg. volume | 2,623 |
| Market cap | 21.07B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 139.75 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.48 (4.26%) |
| Ex-dividend date | 31 Mar 2025 |
| 1y target est | N/A |
- Zacks
Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Thomson Reuters StreetEvents
Q4 2023 Taysha Gene Therapies Inc Earnings Call
Q4 2023 Taysha Gene Therapies Inc Earnings Call
- Reuters
US FDA declines to approve Astellas' gastric cancer drug
Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer. The FDA has not raised any concerns related to the clinical data, and is not requesting additional clinical studies, Astellas said. The company said it is working closely with the FDA and the third-party manufacturer to quickly resolve the regulator's feedback, adding that the decision does not affect any other Astellas product.
